ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease
test for an early AD detectionAlzheimer's disease
test for an early AD detectionAlzheimer's disease  

DETECTION IN CLINICAL PRACTICE

ADmit Therapeutics, S.L. is a company focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.

Rigor RigorOur studies are rigorously analyzed Efficiency EfficiencyWe optimize our own resources Agility AgilityWe adopt agile decisions

TEAMWORK AND INNOVATION

Our technology represents the determination of biomarkers non-related with β-amyloid nor tau.

Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.

News

ADmit appoints Ferran Prat as a Chairman to its Board of Directors
He holds more than 30 years of experience in the Life Science industry mainly in Diagnostics and Pharmaceutical. He has served as CEO, Corporate Vice President of Marketing, Strategic Alliances and Business Development as well as Chief Commercial Officer and Chief Operations ...

read more

OUR TEAM

Ferran Prat Ferran PratChairman of the Board of Directors   
Marta Barrachina Marta BarrachinaCEO
CO-FOUNDER
Member of the Board of Directors     
Giacomo de Simone Giacomo de SimoneMember of the Board of Directors   
Maite Fibla Maite FiblaMember of the Board of Directors   
Horizon 2020 EIT Health NextGenerationEU
This website uses our own cookies and third-party cookies to collect information, in order to improve our services. Your continued use of this website constitutes acceptance of the installation of these cookies. The user has the option of configuring their browser in order to prevent cookies from being installed on their hard drive, although they must keep in mind that doing so may cause difficulties in their use of the webpage. I Agree  How to configure browser